Updated: Novartis revamps cardiovascular commercial strategy as Entresto patent cliff looms
With its decadelong US patent for Entresto set to expire in a few months, Novartis has started to overhaul its commercial approach. The drugmaker is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
